Fig 1.
Model schematic describing the patient pathway of the five treatment options for men with moderate-to-severe LUTS due to BPH.
Abbreviations: BPH, benign prostatic hyperplasia; CT, combination therapy; LUTS, lower urinary tract symptoms; PUL, prostatic urethral lift; PVP, photoselective vaporization of the prostate; TURP, transurethral resection of the prostate; WVTT, water vapor thermal therapy.
Table 1.
Weighted average procedure costs, follow-up costs, subsequent retreatment costs, periprocedural AE costs, short- and long-term AE costs.
Table 2.
IPSS change from baseline to year 5 from the random-effects network meta‐analysis model for use in the base-case cost-effectiveness analyses.
Fig 2.
Medicare per patient costs at year 1 and year 5 for the five treatment options for men with moderate-to-severe lower urinary tract symptoms due to benign prostatic hyperplasia ranging from the least to the most expensive at year 1.
Abbreviations: CT, combination therapy; PUL, prostatic urethral lift; PVP, photoselective vaporization of the prostate; TURP, transurethral resection of the prostate; WVTT, water vapor thermal therapy.
Table 3.
Costs, QALYs, and ICER at 5 years for the five treatment options for men with moderate-to-severe lower urinary tract symptoms due to benign prostatic hyperplasia.
Fig 3.
Scatterplots based on PSAs by comparing CT versus surgical treatments.
a: TURP vs. CT at 5 years. b: PVP vs. CT at 5 years. c: PUL vs. CT at 5 years. d: WVTT vs. CT at 5 years. Abbreviations: CT, combination therapy; PSA, probabilistic sensitivity analysis; PUL, prostatic urethral lift; PVP, photoselective vaporization of the prostate; QALYs, quality-adjusted life years; TURP, transurethral resection of the prostate; WVTT, water vapor thermal therapy.